<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001256685
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MONTAS 4 mg Chewable Tablets
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Chewable tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="OMAN PHARMACEUTICAL PRODUCTS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">&nbsp;<strong>1. What MONTAS Paediatric is and what it is used for </strong></p><p style="text-align:justify">MONTAS Paediatric is a leukotriene receptor antagonist that blocks substances called leukotrienes. Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes, MONTAS Paediatric improves asthma symptoms and helps control asthma.</p><p style="text-align:justify">Your doctor has prescribed MONTAS Paediatric to treat your child&rsquo;s asthma, preventing asthma symptoms during the day and night.</p><ul><li style="text-align: justify;">MONTAS Paediatric is used for the treatment of 2 to 5 year old patients who are not adequately controlled on their medication and need additional therapy.</li><li style="text-align: justify;">MONTAS Paediatric may also be used as an alternative treatment to inhaled corticosteroids for 2 to 5 year old patients who have not recently taken oral corticosteroids for their asthma and have shown that they are unable to use inhaled corticosteroids.</li><li style="text-align: justify;">MONTAS Paediatric also helps prevent the narrowing of airways triggered by exercise for patients 2 years of age and older.</li></ul><p style="text-align:justify">&nbsp;Your doctor will determine how MONTAS Paediatric should be used depending on the symptoms and severity of your child&#39;s asthma.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>What is asthma? </strong></p><p style="text-align:justify">Asthma is a long-term disease.</p><p style="text-align:justify">Asthma includes:</p><ul><li style="text-align: justify;">difficulty breathing because of narrowed airways. This narrowing of airways worsens and improves in response to various conditions.</li><li style="text-align: justify;">sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.</li><li style="text-align: justify;">swelling (inflammation) in the lining of the airways.</li></ul><p style="text-align:justify">Symptoms of asthma include: Coughing, wheezing, and chest tightness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>2. Before MONTAS Paediatric is taken </strong></p><p style="text-align:justify">Tell your doctor about any medical problems or allergies your child has now or has had.</p><p style="text-align:justify"><strong>Do not give MONTAS Paediatric to your child if he/she </strong></p><ul><li style="text-align: justify;">&nbsp;is allergic (hypersensitive) to montelukast or any of the other ingredients of MONTAS Paediatric (see 6. Further information).</li></ul><p style="text-align:justify"><strong>Take special care with MONTAS Paediatric </strong></p><ul><li style="text-align: justify;">If your child&rsquo;s asthma or breathing gets worse, tell your doctor immediately.</li><li style="text-align: justify;">Oral MONTAS Paediatric is not meant to treat acute asthma attacks. If an attack occurs, follow the instructions your doctor has given you for your child. Always have your child&rsquo;s inhaled rescue medicine for asthma attacks with you.</li><li style="text-align: justify;">It is important that your child take all asthma medications prescribed by your doctor. MONTAS Paediatric should not be used instead of other asthma medications your doctor has prescribed for your child.</li><li style="text-align: justify;">&nbsp;If your child is on anti-asthma medicines, be aware that if he/she develops a combination of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.</li><li style="text-align: justify;">&nbsp;Your child should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines (also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make his/her asthma worse.</li></ul><p style="text-align:justify"><strong>Taking other medicines </strong></p><p style="text-align:justify">Some medicines may affect how MONTAS Paediatric works, or MONTAS Paediatric may affect how your child&rsquo;s other medicines work.</p><p style="text-align:justify">Please tell your doctor or pharmacist if your child is taking or has recently taken other medicines, including those obtained without a prescription.</p><p style="text-align:justify">Tell your doctor if your child is taking the following medicines before starting MONTAS Paediatric:</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenobarbital (used for treatment of epilepsy)</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin (used for treatment of epilepsy)</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (used to treat tuberculosis and some other infections)</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Taking MONTAS Paediatric with food and drink </strong></p><p style="text-align:justify">MONTAS Paediatric 4 mg chewable tablets should not be taken immediately with food; they should be taken at least 1 hour before or two hours after food.</p><p style="text-align:justify"><strong>&nbsp;Pregnancy and breast-feeding </strong></p><p style="text-align:justify"><strong>&nbsp;</strong>This subsection is not applicable for the MONTAS Paediatric 4 mg chewable tablets since they are intended for use in children 2 to 5 years of age, however the following information is relevant to the active ingredient, montelukast.</p><p style="text-align:justify"><em>Use in pregnancy </em></p><p style="text-align:justify">Women who are pregnant or intend to become pregnant should consult their doctor before taking MONTAS. Your doctor will assess whether you can take MONTAS during this time.</p><p style="text-align:justify"><em>Use in breast-feeding </em></p><p style="text-align:justify">It is not known if MONTAS appears in breast milk. You should consult your doctor before taking MONTAS if you are breast-feeding or intend to breast-feed.</p><p style="text-align:justify"><strong>Driving and using machines </strong></p><p style="text-align:justify">This subsection is not applicable for the MONTAS Paediatric 4 mg chewable tablets since they are intended for use in children 2 to 5 years of age, however the following information is relevant to the active ingredient, montelukast.</p><p style="text-align:justify">MONTAS is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported very rarely with MONTAS may affect some patients&rsquo; ability to drive or operate machinery.</p><p style="text-align:justify"><strong>Important information about some of the ingredients of MONTAS Paediatric </strong></p><p style="text-align:justify">MONTAS Paediatric chewable tablets contain aspartame, a source of phenylalanine. If your child has phenylketonuria (a rare, hereditary disorder of the metabolism) you should take into account that each MONTAS Paediatric 4 mg chewable tablet contains phenylalanine (equivalent to 0.674 mg phenylalanine per 4 mg chewable tablet).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>3. How to take MONTAS Paediatric </strong></p><ul><li style="text-align: justify;">This medicine is to be given to a child under adult supervision.</li><li style="text-align: justify;">Your child should take only one tablet of MONTAS Paediatric once a day as prescribed by your doctor.</li><li style="text-align: justify;">It should be taken even when your child has no symptoms or if he/she has an acute asthma attack.</li><li style="text-align: justify;">Always have your child take MONTAS Paediatric as your doctor has told you. You should check with your child&rsquo;s doctor or pharmacist if you are not sure.</li><li style="text-align: justify;">To be taken by mouth</li></ul><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>For children 2 to 5 years of age: </strong></p><p style="text-align:justify">One MONTAS Paediatric 4 mg chewable tablet daily to be taken in the evening. MONTAS Paediatric 4 mg chewable tablets should not be taken immediately with food; it should be taken at least 1 hour before or 2 hours after food.</p><p style="text-align:justify">If your child is taking MONTAS Paediatric, be sure that he/she does not take any other medicines that contain the same active ingredient, montelukast.</p><p style="text-align:justify">For children 2 to 5 years old, MONTAS Paediatric 4 mg chewable tablets are available.</p><p style="text-align:justify">For children 6 to 14 years old, MONTAS Paediatric 5 mg chewable tablets are available. The MONTAS Paediatric 4 mg chewable tablet is not recommended below 2 years of age.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>If your child takes more MONTAS Paediatric than he/she should </strong></p><p style="text-align:justify">Contact your child&rsquo;s doctor immediately for advice.</p><p style="text-align:justify">There were no side effects reported in the majority of overdose reports. The most frequently occurring symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>If you forget to give MONTAS Paediatric to your child </strong></p><p style="text-align:justify">Try to give MONTAS Paediatric as prescribed. However, if your child misses a dose, just resume the usual schedule of one tablet once daily.</p><p style="text-align:justify">Do not give a double dose to make up for a forgotten dose.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>If your child stops taking MONTAS Paediatric </strong></p><p style="text-align:justify">MONTAS Paediatric can treat your child&rsquo;s asthma only if your child continues taking it.</p><p style="text-align:justify">It is important for your child to continue taking MONTAS Paediatric for as long as your doctor prescribes. It will help control your child&rsquo;s asthma.</p><p style="text-align:justify">If you have any further questions on the use of this product, ask your child&rsquo;s doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4. Possible side effects </strong></p><p style="text-align:justify">Like all medicines, MONTAS Paediatric can cause side effects, although not everybody gets them.</p><p style="text-align:justify">In clinical studies with MONTAS Paediatric 4 mg chewable tablets, the most commonly reported side effects (occurring in at least 1 of 100 patients and less than 1 of 10 paediatric patients treated) thought to be related to MONTAS Paediatric were:</p><p style="text-align:justify">&middot;&nbsp; &nbsp; abdominal pain</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; thirst</p><p style="text-align:justify">Additionally, the following side effect was reported in clinical studies with MONTAS 10 mg film-coated tablets and 5 mg chewable tablets:</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp;headache</p><p style="text-align:justify">These were usually mild and occurred at a greater frequency in patients treated with MONTAS than placebo (a pill containing no medication).</p><p style="text-align:justify">The frequency of possible side effects listed below is defined using the following convention:</p><p style="text-align:justify">Very common (affects at least 1 user in 10)</p><p style="text-align:justify">Common (affects 1 to 10 users in 100)</p><p style="text-align:justify">Uncommon (affects 1 to 10 users in 1,000)</p><p style="text-align:justify">Rare (affects 1 to 10 users in 10,000)</p><p style="text-align:justify">Very rare (affects less than 1 user in 10,000)</p><p style="text-align:justify">Additionally, while the medicine has been on the market, the following have been reported:</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; upper respiratory infection (<em>Very common</em>)</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp;increased bleeding tendency (<em>Rare</em>)</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp; allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing (<em>Uncommon</em>)</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp;behaviour and mood related changes [dream abnormalities, including nightmares, trouble sleeping, sleep walking, irritability, feeling anxious, restlessness, agitation including</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp;upper respiratory infection (<em>Very common</em>)</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp;increased bleeding tendency (<em>Rare</em>)</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp;allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing (<em>Uncommon</em>)</p><p style="text-align:justify">&middot;&nbsp; &nbsp; behaviour and mood related changes [dream abnormalities, including nightmares, trouble sleeping, sleep walking, irritability, feeling anxious, restlessness, agitation including aggressive behaviour or hostility, depression (<em>Uncommon</em>); tremor (<em>Rare)</em>; hallucinations, disorientation, suicidal thoughts and actions (<em>Very rare</em>)]</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp; dizziness, drowsiness, pins and needles/numbness, seizure (<em>Uncommon</em>)</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;palpitations (<em>Rare</em>)</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;nosebleed (<em>Uncommon</em>)</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; diarrhoea, nausea, vomiting (<em>Common</em>); dry mouth, indigestion (<em>Uncommon</em>)</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;hepatitis (inflammation of the liver) (<em>Very rare</em>)</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;rash <em>(Common)</em>; bruising, itching, hives (<em>Uncommon</em>); tender red lumps under the skin most commonly on your shins (erythema nodosum), severe skin reactions (erythema multiforme) that may occur without warning (<em>Very rare</em>)</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;joint or muscle pain, muscle cramps (<em>Uncommon</em>)</p><p style="text-align:justify">&middot;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; fever (<em>Common</em>); tiredness, feeling unwell, swelling (<em>Uncommon</em>).</p><p style="text-align:justify">In asthmatic patients treated with montelukast, very rare cases of a combination of symptoms such as flu-like illness, pins and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) have been reported. You must tell your doctor right away if your child gets one or more of these symptoms.</p><p style="text-align:justify">Ask your doctor or pharmacist for more information about side effects. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your child&rsquo;s doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>5. How to store MONTAS Paediatric </strong></p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the date shown by the six numbers following EXP on the blister. The first two numbers indicate the month; the last four numbers indicate the year. This medicine expires at the end of the month shown.</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>6. Further information </strong></p><p><strong>What MONTAS Paediatric contains </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is montelukast. Each tablet contains montelukast sodium which corresponds to 4 mg of montelukast.</p><p>The other ingredients are: Mannitol, Microcrystalline cellulose, Croscarmellose sodium, Ethanol 99.9%, Hydroxypropylcellulose, Cherry Flavour SD (290338), Aspartame, Iron oxide red and Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What MONTAS Paediatric looks like and contents of the pack 
Montas 4mg tablets are pink, oval, biconvex tablets.
Aluminium/Aluminium Laminate Foil (OPA/AL/PVC) blister pack of 28 tablets (4 x 7’s) 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zynova/Oman Pharmaceutical Products Co., LLC</p><p>Salalah, Sultanate of Oman</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January 2013 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>1. ما هو مونتاس للأطفال وما هي&nbsp; استخداماته</strong></p><p dir="RTL">&nbsp;مونتاس&nbsp; للأطفال هو مثبط لمستقبلات الليكوتراين الذي يمنع مواد تسمى الليكوترينات.الليكوترينات تسبب ضيق وتورم في الشعب الهوائية في الرئتين. بثبيط الليكوترينات ، مونتاس للأطفال يحسن أعراض الربو ويساعد في السيطرة عليه.</p><p dir="RTL">طبيبك قام بوصف مونتاس للاأطفال لعلاج الربو لدى طفلك، للوقاية من أعراض الربو خلال النهار والليل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يستخدم مونتاس للأطفال لعلاج المرضى من 2 حتى 5 سنوات من العمر الذين لا يسيطر على حالتهم بشكل كاف مع علاجاتهم و يحتاجون الى علاج &nbsp;إضافي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مونتاس للأطفال يمكن أن يستخدم أيضا كعلاج بديل لاستنشاق الكورتيكوستيرويدات للمرضى من السنة 2-5 سنوات من العمر الذين لم يأخذوا &nbsp;مؤخرا الستيرويدات القشرية عن طريق الفم لعلاج الربو وأظهروا بأنهم غير قادرين على استخدام الستيرويدات القشرية المستنشقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مونتاس للأطفال يساعد على منع تضييق الشعب الهوائية الناجم عن ممارسة الرياضة في &nbsp;المرضى من السنة 2 من العمر واكبر.</p><p dir="RTL">&nbsp;طبيبك سوف يحدد الكيفية التي ينبغي أن تستخدم بها مونتاس للأطفال اعتمادا على الأعراض و شدة الربو لدى طفلك.</p><p dir="RTL"><strong>&nbsp;ما هو الربو؟</strong></p><p dir="RTL">&nbsp;الربو هو مرض طويل الأجل.</p><p dir="RTL">الربو يشمل على ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس بسبب ضيق الشعب الهوائية. هذا الضيق في الشعب الهوائية يزداد سوءا ويتحسن استجابة لظروف مختلفة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجارى التنفس الحساسة التي تتفاعل مع عدة أشياء كثيرة، مثل دخان السجائر، غبار الطلع، والهواء البارد، أو ممارسة الرياضة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (التهاب) في بطانة الشعب الهوائية.</p><p dir="RTL">أعراض الربو ما يلي: السعال، وصفير عند التنفس ، وضيق في الصدر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2. قبل اخذ مونتاس للأطفال:</strong></p><p dir="RTL">أخبر طبيبك عن أي مشاكل طبية أو حساسية لدى طفلك الآن أو كانت لديه سابقا.</p><p dir="RTL"><strong>لا تعطي مونتاس للأطفال اذا طفلك هو / هي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لدية حساسية (تفاعل فرط الحساسية) لمونتيلوكاست أو أي من المكونات الأخرى لمونتاس للأطفال (انظر 6. لمزيد من المعلومات).</p><p dir="RTL"><strong>اخذ الحيطة</strong><strong>&nbsp; مع مونتاس للأطفال </strong><strong>: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان الربو او التنفس لدى طفلك يسوء، أخبر طبيبك فورا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مونتاس للاطفال عن طريق الفم ليس المقصود&nbsp; به علاج نوبات الربو الحادة. اذا حصلت نوبة الربو، اتبع التعليمات التي&nbsp; أعطاك الطبيب لطفلك دائما ابقي أدوية طفلك المنقذة من نوبات الربو والتي تستخدم عن طريق الاستنشاق معك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;من المهم أن يأخذ طفلك جميع أدوية الربو الموصوفة من قبل الطبيب. لا ينبغي أن تستخدم مونتاس للأطفال بدلا من أدوية الربو الأخرى التي تم وصفها من قبل طبيب طفلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان طفلك يستخدم الأدوية المضادة للربو، يجب أن تدرك أنه إذا هو / هي قد تطورت لديه خليط من الاعراض مثل اعراض الانفلونزا و احساس وخز الإبر والدبابيس أو خدر في الذراعين أو الساقين، تفاقم الأعراض الرئوية، و / أو الطفح الجلدي، ويجب عليك استشارة طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن لا يأخذ طفلك حمض أسيتيل الساليسيليك (الأسبرين) أو الأدوية المضادة للالتهابات (المعروف أيضا باسم العقاقير المضادة للالتهابات غير الستيرويدية أو مضادات الالتهاب غير الستيروئيدية) إذ أنها تجعل له / لها الربو أكثر سوءا.</p><p dir="RTL"><strong>تناول أدوية أخرى</strong></p><p dir="RTL">قد تؤثر بعض الأدوية على كيفية عمل مونتاس للأطفال، أو قد يؤثر مونتاس للأطفال على كيفية عمل بعض الأدوية الأخرى لدى طفلك.</p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي إذا كان طفلك يأخذ أو اخذ مؤخرا أدوية أخرى، بما في ذلك تلك التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">أخبر طبيبك إذا كان طفلك يأخذ الأدوية التالية قبل البدء بمونتاس للأطفال:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينوباربيتال (التي تستخدم لعلاج الصرع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينيتوين (المستخدم لعلاج الصرع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الريفامبيسين (المستخدم في علاج السل والأمراض المعدية الأخرى بعض)</p><p dir="RTL"><strong>أخذ مونتاس للأطفال مع الطعام والشراب</strong></p><p dir="RTL">مونتاس للأطفال 4 ملجم&nbsp; للمضغ لا ينبغي أن&nbsp; تؤخذ مع الطعام على الفور، وينبغي أن تؤخذ على الأقل ساعة واحدة قبل الاكل أو بعد الطعام بساعتين.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">هذا القسم الفرعي غير قابل للتطبيق مع&nbsp; أقراص مونتاس للأطفال 4 ملجم للمضغ&nbsp; حيث&nbsp; يقصد منها الاستخدام&nbsp; في الأطفال من السنة&nbsp; 2 الى 5 سنوات من العمر، ولكن المعلومات التالية ذات الصلة العنصر النشط، مونتيلوكاست.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>ا</em><em>لاستخدام في الحمل</em></p><p dir="RTL">يجب على النساء الحوامل أو التي تنوي أن تصبح حاملا استشارة الطبيب قبل اخذ مونتاس. طبيبك سوف يقيم ما إذا كان يمكنك أن تأخذي مونتاس خلال هذه الفترة.</p><p dir="RTL"><em>الا</em><em>ستخدام في الرضاعة </em><em>الطبيعية </em></p><p dir="RTL">ومن غير المعروف إذا ما&nbsp; كان مونتاس يظهر في حليب الثدي. يجب استشارة الطبيب قبل تناول مونتاس إذا كنت مرضعة&nbsp; طبيعيا أو تنوين&nbsp; الإرضاع.</p><p dir="RTL"><strong>القيادة واستخدام الآليات</strong></p><p dir="RTL">هذا القسم الفرعي غير قابل للتطبيق مع&nbsp; أقراص للأطفال&nbsp; 4 ملجم للمضغ حيث يقصد منها استخدامها في الأطفال من&nbsp; 2 الى 5 سنوات من العمر، ولكن المعلومات التالية ذات الصلة العنصر النشط، مونتيلوكاست.</p><p dir="RTL">مونتاس ليس من المتوقع أن يؤثر على القدرة على قيادة السيارة أو تشغيل الآلات. ومع ذلك، فإن الردود الفردية على الأدوية تختلف. بعض الآثار الجانبية المعينة (مثل الدوخة والنعاس) التي تم الإبلاغ عنها في حالات نادرة جدا مع مونتاس قد تؤثر على قدرة بعض المرضى على القيادة أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات مونتاس للاطفال</strong></p><p dir="RTL">أقراص المضغ مونتاس للأطفال تحتوي على الأسبارتام، مصدرا للفينيل ألانين. إذا كان طفلك يعاني بيلة الفينيل كيتونيوريا (نادرة، واضطراب وراثي في ​​التمثيل الغذائي) يجب أن تأخذ في الاعتبار أن اقراص المضغ مونتاس للأطفال 4 ملجم تحتوي على الفينيل ألانين (ما يعادل 0.674 ملجم منفينيل الأنين لكل قرص مضغ 4 ملجم).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>3. كيفية اخذ مونتاس للأطفال</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذا الدواء الذي يعطى لطفل تحت إشراف الكبار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يأخذ طفلك فقط حبة واحدة من مونتاس للأطفال مرة واحدة في اليوم على النحو الذي يحدده الطبيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي اخذه حتى كان طفلك هو/هي ليس لديه اعراض&nbsp; نوبة الربو الحادة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دائما تأكد من أخذ طفلك مونتاس للأطفال &nbsp;حسب تعليمات الطبيب . يجب عليك التحقق مع طبيب طفلك او الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يؤخذ عن طريق الفم</p><p dir="RTL"><strong>&nbsp;للأطفال من سن 2 إلى 5 سنوات من العمر:</strong></p><p dir="RTL">&nbsp;قرص واحد للمضغ من مونتاس للأطفال 4 ملجم يوميا يتم أخذه&nbsp; في المساء. اقراص مونتاس للأطفال 4 ملجم لا ينبغي أن تؤخذ مباشرة بعد الطعام ، وينبغي أن تؤخذ على الأقل ساعة واحدة قبل الاكل أو بعد الطعام بساعتين.</p><p dir="RTL">إذا كان طفلك يأخذ مونتاس للأطفال، تأكد أنه / أنها لا تأخذ أي أدوية أخرى تحتوي على نفس العنصر النشط، مونتيلوكاست.</p><p dir="RTL">لأطفال في سن 2 إلى 5 سنوات من العمر، أقراص مونتاس للأطفال 4 ملجم&nbsp; للمضغ متوفرة.</p><p dir="RTL">لأطفال في سن 6 إلى 14 سنة، أقراص مونتاس للأطفال 5 ملجم&nbsp; للمضغ متوفرة. لا ينصح باستخدام&nbsp; اقراص مونتاس 4 ملجم للمضغ لمن هم&nbsp; أقل من 2 سنة من العمر.</p><p dir="RTL"><strong>إذا أخذ طفلك كمية أكثر من الازم من مونتاس للأطفال ينبغي له / لها</strong></p><p dir="RTL">اتصل بطبيب طفلك على الفور للحصول على المشورة.</p><p dir="RTL">لم تكن هناك آثار جانبية ذكرت في معظم تقارير الجرعة الزائدة. معظم الأعراض الشائعة التي تحدث مع الجرعة الزائدة ذكرت في البالغين والأطفال هي&nbsp; آلام في البطن، والنعاس، والعطش والصداع والقيء، وفرط النشاط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;إذا نسيت أن تعطي مونتاس لطفلك</strong></p><p dir="RTL">حاول إعطاء مونتاس للأطفال على&nbsp; النحو المنصوص عليه. ومع ذلك، إذا كان طفلك يفوت جرعة استئنف الجدول الزمني المعتاد فقط من قرص واحد مرة واحدة يوميا.</p><p dir="RTL">لا تعطي جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقف طفلك عن&nbsp; اخذ&nbsp; مونتاس للأطفال</strong></p><p dir="RTL">مونتاس للأطفال يمكن أن يعالج الربو لدى طفلك فقط إذا استمر طفلك بأخذه بصفه مستمرة.</p><p dir="RTL">من المهم لطفلك الاستمرار في اخذ مونتاس للأطفال بطول الفترة التي وصفها الطبيب. وسوف يساعد في السيطرة على الربو لدى طفلك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، اسأل طبيب طفلك او الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;4. الآثار الجانبية المحتملة</strong></p><p dir="RTL">مثل جميع الأدوية، يمكن لمونتاس للأطفال أن يتسبب في آثار جانبية، وإن لم يكن الجميع تحصل لديه.</p><p dir="RTL">في الدراسات السريرية مع أقراص المضغ مونتاس للأطفال 4 ملجم، والآثار الجانبية الأكثر شيوعا (وقعت في ما لا يقل عن 1 من 100 مريض وتم علاج أقل من 1 من 10 مرضى الأطفال) يعتقد أن لها صلة بمونتاس للأطفال هي :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العطش</p><p dir="RTL">بالإضافة إلى ذلك، أفادت تقارير الدراسات السريرية الآثار الجانبية التالية مع أقراص مونتاس المغلفة بفيلم 10 ملجم و 5 ملجم للمضغ:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">وكانت هذه الاعراض عادة ما تكون خفيفة وقعت &nbsp;بمعدل أكثر في المرضى الذين يأخذون مونتاس&nbsp; من الذين يأخذون العلاج الوهمي البلاسيبو (الحبوب التي لا تحتوي على الدواء).</p><p dir="RTL">الاثار الجانبية المحتملة الأكثر تكرارا يتم تعريفها كما هو مذكور أدناه باستخدام المصطلحات التالية:</p><p dir="RTL">شائعة جدا (حدثت&nbsp; في 1 من كل 10 مستخدم )</p><p dir="RTL">الشائعة (حدتث في 1 إلى 10 من كل 100 مستخدم )</p><p dir="RTL">الغير شائعة ( حدثت في 1 إلى 10 من كل&nbsp; 1000 مستخدم )</p><p dir="RTL">النادرة (حدثت في 1 إلى 10 من كل&nbsp; 10000 مستخدم )</p><p dir="RTL">النادرة جدا (حدثت في أقل من 1 مستخدم من كل 10000 مستخدم)</p><p dir="RTL">بالإضافة إلى ذلك، بعد تسويق الدواء، تم الإبلاغ عن ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي (شائعة جدا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;زيادة الميل للنزيف (نادرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الحساسية بما في ذلك تورم في الوجه والشفتين واللسان، و / أو الحلق مما قد يسبب صعوبة في التنفس أو البلع (غير شائعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التغيرات ذات الصلة بالسلوك والمزاج [شذوذ في الحلم، بما في ذلك الكوابيس، اضطرابات النوم، المشي أثناء النوم، والانفعالية، والشعور بالقلق، والأرق، والتهيج بما في ذلك السلوك العدواني أو العدائية، والاكتئاب (غير شائعة)؛ الارتعاش (نادرة)؛ الهلوسة، التوهان، والأفكار و الافعال الانتحارية (نادرة جدا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الدوخة، والخمول، احساس وخز دبابيس والإبر / خدر، ورعشة (غير شائعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;خفقان (نادرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرعاف (غير شائعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، والغثيان، والتقيؤ (عام)؛ جفاف الفم، وعسر الهضم (غير شائع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد (التهاب الكبد) (نادرة جدا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي (عام)؛ التكدم، والحكة، والشرى (غير شائع)؛ كتل حمراء طرية تحت الجلد أكثر شيوعا على السيقان (حمامي عقدية)، تفاعلات جلدية خطيرة (حمامي عديدة الأشكال) قد تحدث دون سابق إنذار (نادرة جدا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل أو العضلات، وتشنجات العضلات (غير شائعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (شائعة)؛ التعب، والشعور بالإعياء، وتورم (غير شائعة)</p><p dir="RTL">في مرضى الربو الذين يستخدمون مونتيلوكاست، في حالات نادرة جدا خليط من الاعراض مثل اعراض مرض الانفلونزا و احساس وخز الإبر والدبابيس أو خدر في الذراعين والساقين، تفاقم الأعراض الرئوية و / أو طفح (شيرغ ستروس متلازمة) قد تم الابلاغ. يجب عليك إخبار الطبيب على الفور إذا كان طفلك ظهرت لديه أي واحدة أو أكثر من هذه الأعراض.</p><p dir="RTL">إسأل طبيبك أو الصيدلي للحصول على مزيد من المعلومات حول الآثار الجانبية. إذا كان أي من الآثار الجانبية اصبحت خطيرة ، أو إذا لاحظت أي آثار جانبية غير المدرجة في هذه النشرة، يرجى إخبار طبيب طفلك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>5. كيفية تخزين أقراص مونتاس للأطفال:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحفظ بعيدا عن متناول وبصر الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;لا تستخدم هذا الدواء بعد تاريخ الاتنهاء المبين بالأرقام الستة التي تلي&nbsp; EXP على الشريط. أول رقمين يشيران إلى الشهر؛ الأربعة الأخيرة تشير الأرقام السنة. تاريخ انتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30&nbsp; درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>6. المزيد من المعلومات</strong></p><p dir="RTL"><strong>&nbsp;على ماذا يحتوي مونتاس للأطفال</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة النشطة هي مونتيلوكاست. كل قرص يحتوي على مونتيلوكاست الصوديوم والتي تطابق 4 ملجم من المونتيلوكاست.</p><p>المكونات الأخرى هي: المانيتول، ميكروكرستالين السليلوز ، كروسكارميلوز الصوديوم ، الإيثانول 99.9٪، هايدوكسيبروبايلسيليلوز، مكسبات طعم الكرز ( SD 290338)، الأسبارتام، أكسيد الحديد الأحمر وستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>ما هو شكل مونتاس للأطفال ومحتويات العبوة</strong></p><p dir="RTL" style="text-align:right">أقراص مونتاس 4 ملجم وردية اللون بيضاوية&nbsp; ثنائية التحدب في الشكل.</p><p dir="RTL" style="text-align:right">صفائح رقيقة من الألمنيوم / الألومنيوم (OPA / AL / PVC) عبوةمن شرائط من 28 قرص (4 &times; 7 )</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حامل ترخيص التسويق و المصنّع</strong></p><p dir="RTL">الشركة العمانية لمستحضرات الصيدلة ش م م</p><p dir="RTL">&nbsp;صلالة، سلطنة عمان</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاريخ اصدار هذه النشرة:   يناير2013

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Montas 4mg Chewable tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains Montelukast Sodium IHS 4.15mg equivalent to Montelukast 4mg.

Excipients are mannitol, microcrystalline cellulose, Croscarmellose sodium, Ethanol 99.9%, Hydroxypropylcellulose, Cherry Flavour SD (290338), Aspartame, Iron oxide red and Magnesium stearate

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Montas 4mg tablets are pink, oval, biconvex tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">MONTAS is indicated in the treatment of asthma as add-on therapy in those 2 to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &#39;as-needed&#39; short-acting &beta;-agonists provide inadequate clinical control of asthma.</p><p style="text-align:justify">MONTAS may also be an alternative treatment option to low-dose inhaled&nbsp; corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.2).</p><p style="text-align:justify">MONTAS is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">This medicinal product is to be given to a child under adult supervision. The dosage for paediatric patients 2-5 years of age is one 4 mg chewable tablet daily to be taken in the evening. If taken in connection with food, MONTAS should be taken 1 hour before or 2 hours after food. No dosage adjustment within this age group is necessary. The MONTAS Paediatric 4 mg chewable tablet formulation is not recommended below 2 years of age.</p><p style="text-align:justify"><em>General recommendations</em>:</p><p style="text-align:justify">The therapeutic effect of MONTAS on parameters of asthma control occurs within one day. Patients should be advised to continue taking MONTAS even if their asthma is under control, as well as during periods of worsening asthma.</p><p style="text-align:justify">No dosage adjustment is necessary for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.</p><p style="text-align:justify">MONTAS <em>as an alternative treatment option to low-dose inhaled corticosteroids for mild, persistent asthma:</em></p><p style="text-align:justify"><em>&nbsp;</em>Montelukast is not recommended as monotherapy in patients with moderate persistent asthma. The use of montelukast as an alternative treatment option to low-dose inhaled corticosteroids for children with mild persistent asthma should only be considered for patients who do not have a recent history of serious asthma attacks that required oral corticosteroid use and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.1). Mild persistent asthma is defined as asthma symptoms more than once a week but less than once a day, nocturnal symptoms more than twice a month but less than once a week, normal lung function between episodes. If satisfactory control of asthma is not achieved at follow-up (usually within one month), the need for an additional or different anti-inflammatory therapy based on the step system for asthma therapy should be evaluated. Patients should be periodically evaluated for their asthma control.</p><p style="text-align:justify"><em>MONTAS as prophylaxis of asthma for 2 to 5 year old patients in whom the predominant component is exercise-induced bronchoconstriction</em>.</p><p style="text-align:justify">In 2 to 5 year old patients, exercise-induced bronchoconstriction may be the predominant manifestation of persistent asthma that requires treatment with inhaled corticosteroids. Patients should be evaluated after 2 to 4 weeks of treatment with montelukast. If satisfactory response is not achieved, an additional or different therapy should be considered.</p><p style="text-align:justify"><em>Therapy with </em>MONTAS <em>in relation to other treatments for asthma.</em></p><p style="text-align:justify">When treatment with MONTAS is used as add-on therapy to inhaled corticosteroids, MONTAS should not be abruptly substituted for inhaled corticosteroids (see section 4.4).</p><p style="text-align:justify">10 mg film-coated tablets are available for adults 15 years of age and older.</p><p style="text-align:justify">5 mg chewable tablets are available for paediatric patients 6 to 14 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled &beta;-agonist should be used. Patients should seek their doctor&#39;s advice as soon as possible if they need more inhalations of short-acting &beta;- agonists than usual.</p><p style="text-align:justify">Montelukast should not be abruptly substituted for inhaled or oral corticosteroids.</p><p style="text-align:justify">There are no data demonstrating that oral corticosteroids can be reduced when montelukast is given concomitantly.</p><p style="text-align:justify">In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases usually, but not always, have been associated with the reduction or withdrawal of oral corticosteroid therapy. The possibility that leukotriene receptor antagonists may be associated with emergence of Churg-Strauss syndrome can neither be excluded nor established. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.</p><p style="text-align:justify">MONTAS contains aspartame, a source of phenylalanine. Patients with phenylketonuria should take into account that each 4 mg chewable tablet contains phenylalanine in an amount equivalent to 0.674 mg phenylalanine per dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl oestradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since montelukast is metabolised by CYP 3A4, caution should be exercised, particularly in children, when montelukast is co-administered with inducers of CYP 3A4, such as phenytoin, phenobarbital and rifampicin.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>In vitro </em>studies have shown that montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolised by CYP 2C8) demonstrated that montelukast does not inhibit CYP 2C8 <em>in vivo. </em>Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (eg., paclitaxel, rosiglitazone, and repaglinide).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em><u>Use during pregnancy</u></em></p><p style="text-align:justify"><em>&nbsp;</em>Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.</p><p style="text-align:justify">Limited data from available pregnancy databases do not suggest a causal relationship between MONTAS and malformations (i.e. limb defects) that have been rarely reported in worldwide post marketing experience.</p><p style="text-align:justify">MONTAS may be used during pregnancy only if it is considered to be clearly essential.</p><p style="text-align:justify"><em><u>Use during lactation</u></em></p><p style="text-align:justify"><em>&nbsp;</em>Studies in rats have shown that montelukast is excreted in milk (see section 5.3). It is not known if montelukast is excreted in human milk.</p><p style="text-align:justify">MONTAS may be used in breast-feeding mothers only if it is considered to be clearly essential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Montelukast is not expected to affect a patient&#39;s ability to drive a car or operate machinery. However, in very rare cases, individuals have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Montelukast has been evaluated in clinical studies as follows:</p><p style="text-align:justify">&bull;&nbsp; 10 mg film-coated tablets in approximately 4,000 adult patients 15 years of age and older, and</p><p style="text-align:justify">&bull;&nbsp; 5 mg chewable tablets in approximately 1,750 paediatric patients 6 to 14 years of age.</p><p style="text-align:justify">&bull;&nbsp; 4 mg chewable tablets in 851 paediatric patients 2 to 5 years of age.</p><p style="text-align:justify">Montelukast has been evaluated in a clinical study in patients with intermittent asthma as follows:</p><p style="text-align:justify">&bull;&nbsp; 4 mg granules and chewable tablets in 1038 paediatric patients 6 months to 5 years of age</p><p style="text-align:justify">The following drug-related adverse reactions in clinical studies were reported commonly (&ge;1/100 to &lt;1/10) in patients treated with montelukast and at a greater incidence than in patients treated with placebo:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body System Class</strong></p></td><td style="vertical-align:top"><p><strong>Adult Patients 15</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric Patients</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric Patients</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>years and older</strong></p><p><strong>(two 12-week studies; n=795)</strong></p></td><td style="vertical-align:top"><p><strong>6 to 14 years old</strong></p><p><strong>(one 8-week study; n=201)</strong></p><p><strong>(two 56-week studies; n=615)</strong></p></td><td style="vertical-align:top"><p><strong>2 to 5 years old</strong></p><p><strong>(one 12-week study; n=461)</strong></p><p><strong>(one 48-week study; n=278)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastro-intestinal disorders</strong></p></td><td style="vertical-align:top"><p>abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>thirst</p></td></tr></tbody></table><p>With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12 months for paediatric patients 6 to 14 years of age, the safety profile did not change.</p><p>Cumulatively, 502 paediatric patients 2 to 5 years of age were treated with montelukast for at least 3 months, 338 for 6 months or longer, and 534 patients for 12 months or longer. With prolonged treatment, the safety profile did not change in these patients either.</p><p>Post-marketing Experience</p><p>Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse Experience Term, in the table below. Frequency Categories were estimated based on relevant clinical trials.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Experience Term</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Category*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>upper respiratory infection<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>increased bleeding tendency</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorder</p></td><td style="vertical-align:top"><p>hypersensitivity reactions including anaphylaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>hepatic eosinophilic infiltration</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>dream abnormalities including nightmares, insomnia, somnambulism, irritability, anxiety, restlessness, agitation including aggressive behaviour or hostility, depression</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>tremor</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>hallucinations, disorientation, suicidal thinking and behaviour (suicidality)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorder</p></td><td style="vertical-align:top"><p>dizziness, drowsiness</p><p>paraesthesia/hypoesthesia, seizure</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>palpitations</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Churg-Strauss Syndrome (CSS) (see section 4.4)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>diarrhoea<sup>&Dagger;</sup>, nausea<sup>&Dagger;</sup>, vomiting<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>dry mouth, dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>elevated levels of serum transaminases (ALT, AST)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury).</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>rash<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>bruising, urticaria, pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>angiooedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>erythema nodosum, erythema multiforme</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal, connective tissue and bone disorders</p></td><td style="vertical-align:top"><p>arthralgia, myalgia including muscle cramps</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>pyrexia<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>asthenia/fatigue, malaise, oedema,</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p>*Frequency Category: Defined for each Adverse Experience Term by the incidence reported in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to</p><p>&lt;1/10), Uncommon (&ge;1/1000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1000), Very Rare (&lt;1/10,000).</p><p><sup>&dagger;</sup>This adverse experience, reported as Very Common in the patients who received montelukast, was also reported as Very Common in the patients who received placebo in clinical trials.</p><p><sup>&Dagger;</sup>This adverse experience, reported as Common in the patients who received montelukast, was also reported as Common in the patients who received placebo in clinical trials.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">1.1 Overdose</p><p style="text-align:justify"><strong>&nbsp;</strong>No specific information is available on the treatment of overdose with montelukast. In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to patients for 22 weeks and in short-term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences.</p><p style="text-align:justify">There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast. These include reports in adults and children with a dose as high as 1000 mg (approximately 61 mg/kg in a 42 month old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. There were no adverse experiences in the majority of overdose reports. The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.</p><p style="text-align:justify">It is not known whether montelukast is dialysable by peritoneal- or haemo-dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Pharmacotherapeutic group: </strong>Leukotriene receptor antagonist</p><p style="text-align:justify"><strong>ATC Code: </strong>RO3D CO3</p><p style="text-align:justify">The cysteinyl leukotrienes (LTC<sub>4</sub>, LTD<sub>4</sub>, LTE<sub>4</sub>) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro- asthmatic mediators bind to cysteinyl leukotriene receptors (CysLT) found in the human airway and cause airway actions, including bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment.</p><p style="text-align:justify">Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT<sub>1</sub> receptor. In clinical studies, montelukast inhibits bronchoconstriction due to inhaled LTD<sub>4</sub> at doses as low as 5 mg. Bronchodilation was observed within two hours of oral administration. The bronchodilation effect caused by a &beta;-agonist was additive to that caused by montelukast. Treatment with montelukast inhibited both early- and late- phase bronchoconstriction due to antigen challenge. Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and paediatric patients. In a separate study, treatment with montelukast significantly decreased eosinophils in the airways (as measured in sputum). In adult and paediatric patients 2 to 14 years of age, montelukast, compared with placebo, decreased peripheral blood eosinophils while improving clinical asthma control.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In studies in adults, montelukast 10 mg once daily, compared with placebo, demonstrated significant improvements in morning FEV<sub>1</sub> (10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant decrease in total &beta;-agonist use (-26.1% vs -4.6% change from baseline). Improvement in patient-reported daytime and night-time asthma symptoms scores was significantly better than placebo.</p><p style="text-align:justify">Studies in adults demonstrated the ability of montelukast to add to the clinical effect of inhaled corticosteroid (% change from baseline for inhaled beclometasone plus montelukast vs beclometasone, respectively for FEV<sub>1</sub> : 5.43% vs 1.04%; &beta;-agonist use: - 8.70% vs 2.64%). Compared with inhaled beclometasone (200 &mu;g twice daily with a spacer device), montelukast demonstrated a more rapid initial response, although over the 12-week study, beclometasone provided a greater average treatment effect (% change from baseline for montelukast vs beclometasone, respectively for FEV<sub>1</sub> : 7.49% vs 13.3%; &beta;-agonist use: -28.28% vs -43.89%). However, compared with beclometasone, a high percentage of patients treated with montelukast achieved similar clinical responses (e.g. 50% of patients treated with beclometasone achieved an improvement in FEV<sub>1</sub> of approximately 11% or more over baseline while approximately 42% of patients treated with montelukast achieved the same response).</p><p style="text-align:justify">In a 12-week, placebo-controlled study in paediatric patients 2 to 5 years of age, montelukast 4 mg once daily improved parameters of asthma control compared with placebo irrespective of concomitant controller therapy (inhaled/nebulised corticosteroids or inhaled/nebulised sodium cromoglycate). Sixty percent of patients were not on any other controller therapy. Montelukast improved daytime symptoms (including coughing, wheezing, trouble breathing and activity limitation) and night-time symptoms compared with placebo. Montelukast also decreased &#39;as needed&#39; &beta;-agonist use and corticosteroid rescue for worsening asthma compared with placebo. Patients receiving montelukast had more days without asthma than those receiving placebo. A treatment effect was achieved after the first dose.</p><p style="text-align:justify">In a 12-month, placebo-controlled study in paediatric patients 2 to 5 years of age with mild asthma and episodic exacerbations, montelukast 4 mg once daily significantly (p&le; 0.001) reduced the yearly rate of asthma exacerbation episodes (EE) compared with</p><p style="text-align:justify">placebo (1.60 EE vs. 2.34 EE, respectively), [EE defined as &ge; 3 consecutive days with daytime symptoms requiring &beta;-agonist use, or corticosteroids (oral or inhaled), or hospitalisation for asthma]. The percentage reduction in yearly EE rate was 31.9%, with a 95% CI of 16.9, 44.1.</p><p style="text-align:justify">In a placebo-controlled study in paediatric patients 6 months to 5 years of age who had intermittent asthma but did not have persistent asthma, treatment with montelukast was administered over a 12-month period, either as a once-daily 4 mg regimen or as a series of 12-day courses that each were started when an episode of intermittent symptoms began. No significant difference was observed between patients treated with montelukast 4 mg or placebo in the number of asthma episodes culminating in an asthma attack, defined as an asthma episode requiring utilization of health-care resources such as an unscheduled visit to a doctor&#39;s office, emergency room, or hospital or treatment with oral, intravenous, or intramuscular corticosteroid.</p><p style="text-align:justify">In an 8-week study in paediatric patients 6 to 14 years of age, montelukast 5 mg once daily, compared with placebo, significantly improved respiratory function (FEV<sub>1</sub> 8.71% vs 4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change from baseline) and decreased &#39;as-needed&#39; &beta;-agonist use (-11.7% vs +8.2% change from baseline).</p><p style="text-align:justify">In a 12-month study comparing the efficacy of montelukast to inhaled fluticasone on asthma control in paediatric patients 6 to 14 years of age with mild persistent asthma, montelukast was non-inferior to fluticasone in increasing the percentage of asthma rescue-free days (RFDs), the primary endpoint. Averaged over the 12-month treatment period, the percentage of asthma RFDs increased from 61.6 to 84.0 in the montelukast group and from 60.9 to 86.7 in the fluticasone group. The between group difference in LS mean increase in the percentage of asthma RFDs was statistically significant (-2.8 with a 95% CI of -4.7, -0.9), but within the limit pre-defined to be clinically not inferior. Both montelukast and fluticasone also improved asthma control on secondary variables assessed over the 12 month treatment period:</p><p style="text-align:justify">&bull;&nbsp; FEV<sub>1</sub> increased from 1.83 L to 2.09 L in the montelukast group and from 1.85 L to 2.14 L in the fluticasone group. The between-group difference in LS mean increase in FEV<sub>1</sub> was -0.02 L with a 95% CI of -0.06, 0.02. The mean increase from baseline in % predicted FEV<sub>1</sub> was 0.6% in the montelukast treatment group, and 2.7% in the fluticasone treatment group. The difference in LS means for the change from baseline in the % predicted FEV<sub>1</sub> was significant: -2.2% with a 95% CI of -3.6, -0.7.</p><p style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp;&nbsp; The percentage of days with &beta;-agonist use decreased from 38.0 to 15.4 in the montelukast group, and from 38.5 to 12.8 in the fluticasone group. The between group difference in LS means for the percentage of days with &beta;-agonist use was significant: 2.7 with a 95% CI of 0.9, 4.5.</p><p style="text-align:justify">&bull;&nbsp;&nbsp; The percentage of patients with an asthma attack (an asthma attack being defined as a period of worsening asthma that required treatment with oral steroids, an unscheduled visit to the doctor&#39;s office, an emergency room visit, or hospitalisation) was 32.2 in the montelukast group and 25.6 in the fluticasone group; the odds ratio (95% CI) being significant: equal to 1.38 (1.04, 1.84).</p><p style="text-align:justify">&bull;&nbsp;&nbsp; The percentage of patients with systemic (mainly oral) corticosteroid use during the study period was 17.8% in the montelukast group and 10.5% in the fluticasone group. The between group difference in LS means was significant: 7.3% with a 95% CI of 2.9; 11.7.</p><p style="text-align:justify">Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12-week study in adults (maximal fall in FEV<sub>1</sub> 22.33% for montelukast vs 32.40% for placebo; time to recovery to within 5% of baseline FEV<sub>1</sub> 44.22 min vs 60.64 min). This effect was consistent throughout the 12-week study period. Reduction in EIB was also demonstrated in a short term study in paediatric patients 6 to 14 years of age (maximal fall in FEV<sub>1</sub> 18.27% vs 26.11%; time to recovery to within 5% of baseline FEV<sub>1</sub> 17.76 min vs 27.98 min). The effect in both studies was demonstrated at the end of the once- daily dosing interval.</p><p style="text-align:justify">In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with montelukast, compared with placebo, resulted in significant improvement in asthma control (FEV<sub>1</sub> 8.55% vs -1.74% change from baseline and decrease in total &beta;-agonist use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Absorption: </em>Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated tablet, the mean peak plasma concentration (C<sub>max</sub>) is achieved three hours (T<sub>max</sub>) after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and C<sub>max</sub> are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10 mg film-coated tablet was administered without regard to the timing of food ingestion.</p><p style="text-align:justify">For the 5 mg chewable tablet, the C<sub>max</sub> is achieved in two hours after administration in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.</p><p style="text-align:justify">After administration of the 4 mg chewable tablet to paediatric patients 2 to 5 years of age in the fasted state, C<sub>max</sub> is achieved 2 hours after administration. The mean C<sub>max</sub> is 66% higher while mean C<sub>min</sub> is lower than in adults receiving a 10 mg tablet.</p><p style="text-align:justify"><em>Distribution: </em>Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of montelukast averages 8-11 litres. Studies in rats with radiolabelled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabelled material at 24 hours post-dose were minimal in all other tissues.</p><p style="text-align:justify"><em>Biotransformation: </em>Montelukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and children.</p><p style="text-align:justify"><em>In vitro </em>studies using human liver microsomes indicate that cytochromes P450 3A4, 2A6 and 2C9 are involved in the metabolism of montelukast. Based on further <em>in vitro </em>results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.</p><p style="text-align:justify"><em>Elimination</em>: The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabelled montelukast, 86% of the radioactivity was recovered in 5-day faecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively <em>via </em>the bile.</p><p style="text-align:justify"><em>Characteristics in patients: </em>No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (Child-Pugh score &gt;9).</p><p style="text-align:justify">With high doses of montelukast (20- and 60-fold the recommended adult dose), a decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were observed which were transient in nature. The signs of toxicity in animals were increased excretion of saliva, gastro-intestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic exposure seen at the clinical dosage. In monkeys, the adverse effects appeared&nbsp; at doses from 150 mg/kg/day ( &gt;232-fold the systemic exposure seen at the clinical dose). In animal studies, montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200 mg/kg/day ( &gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals, was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.</p><p style="text-align:justify">No deaths occurred following a single oral administration of montelukast sodium at doses up to 5000 mg/kg in mice and rats (15,000 mg/m<sup>2</sup> and 30,000 mg/m<sup>2</sup> in mice and rats,</p><p style="text-align:justify">respectively) the maximum dose tested. This dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).</p><p style="text-align:justify">Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic exposure).</p><p style="text-align:justify">Montelukast was neither mutagenic in <em>in vitro </em>and <em>in vivo </em>tests nor tumorigenic in rodent species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Excipients are mannitol, microcrystalline cellulose, Croscarmellose sodium, Ethanol 99.9%, Hydroxypropylcellulose, Cherry Flavour SD (290338), Aspartame, Iron oxide red and Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>KEEP OUT OF THE REACH OF CHILDREN</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/Aluminium Laminate Foil (OPA/AL/PVC) blister pack of 28 tablets (4 x 7&rsquo;s)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OMAN PHARMACEUTICAL PRODUCTS CO. L.L.C. Salalah, Sultanate of Oman
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>